Treatment of Ebola Virus Disease with Bacterial Co-infection in Children (Older Than 4 Weeks) and Adolescents

In children older than 4 weeks and adolescents with Ebola virus disease, bacterial co-infection can complicate the clinical course and requires specific management. When severe disease is present alongside bacterial co-infection, antibiotic therapy is a key component of the overall treatment plan.

Clinical Scenario

This protocol addresses children older than 4 weeks and adolescents who have Ebola virus disease complicated by bacterial co-infection in the setting of severe disease. Managing this co-infection appropriately is a critical and time-sensitive element of care in this age group.

Treatment Approach (Summary)

The regimen for bacterial co-infection in this population centres on intravenous antibiotic therapy. A broad-spectrum beta-lactam antibiotic is typically the primary agent, with consideration of additional anaerobic coverage depending on the clinical presentation. Age-specific dosing parameters apply across this paediatric and adolescent age range.

Full regimen, agent selection, and age-specific details available in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

Severe disease: IV ceftriaxone (usually 5 days).

4 weeks–10 years: 50–100 mg/kg once daily

10–17 years: 1–2 g once daily.

+/- IV metronidazole (usually 7 days): 7.5 mg/kg 8 hourly; maximum dose 500 mg.

View source ↗